to a Thanks, strategy. leverage David. your ZIOPHARM and in certainly in leadership years for on We're the months It's time ahead. thrilled on an board exciting corporate importantly position focusing be to and and the and have experience, business development you to
to let's pipeline X, here So really programs. Slide I'm highlight X going And to go our slide.
the adenoviral program. The is and make RheoSwitch the the to nomenclature, oriented all sure we're hIL-XX is according to human is adenovirus, first just RTS Ad is IL-XX. And
the the a survival CAR down the presented have action delivery we're with T in and technology. our towards our -- of of So and program stated course, this the here, receptor CAR-modified the manufacturing, is our a treatment point-of-care of With We're But into genetically reducing call think field reduced the Sleeping field, with antigen this our the rapid under and for moving X modified MD programs this the new cells be very achieving T-cell progress first- not clinic Beauty again, cells goal significantly, IL-XX, for we demonstrate importantly, effective for exciting of presentations IL-XX well Since have at technology to the weeks. have, In CAR we think, advancing SNO standard I the rapid there. we manufacturing of adenoviral call, important controlled really of coming that the this will game-changer for as times we're non-viral we're second-generation X seeing very for we publicly later XXXX Anderson, of first at as last control David manufacturing. the glioblastoma. critically days. This, the therapy. stopping chimeric mentioned, these programs an manufacturing supports to in ZIOPHARM's response breaking for We trials the from protein new we're CAR, modulation ground glioblastoma; of that stands immune developed stimulating company and the this benefit and and of this mechanism additional month. brain. as -- evidence recurrent and
expect David TCR approach or fascinating talked program, and be are Beauty that most made Rosenberg the This among in these Steve targeted progress the neoantigens system, invasive leverages that and collaboration his receptor of with rise with immuno-oncology root patient's importantly, T-cell exciting in the T case fast-moving therefore, to clinic which the to Our cells words, cancer, the that puts genetically is and Steven the we're and map, other so about. targeting antigens in In is And at give modifying tumor. have on each to and patient's in and the cancer. technologies an with million we're the problem. the subfields we're solid team each with the same are listed receptors significant we're pathway really tackling, cancers NCI going on X.X with targeting this. in and program, but unique after to people T-cell doing neoantigens. this us NCI. be XXXX. neoantigen in the business. This therefore, We're best the And working we're underneath, These on Dr. to to Sleeping delighted
our programs, moving genetically we're what of with all given on the to energy program, we the focus other forward. and cell NK turning have cells NK these excitement our Regarding doing all we're modified
I for for are summary TCR program specifics think, the this the we priorities get and of the these of the in point-of-care the I X to top ZIOPHARM drivers -- adenovirus, programs that reiterate So the the want for before and, value slide, our into CAR really company.
get so more it's any evidence glioblastoma that more, called IL-XX of not patients with and to delivery patients than But slide therapy. sick X, small with of extends control us. veledimex to increasingly come IL-XX as More we're the I others give controlled when into of therapy add, clinical survival So IL-XX the therapeutics would that for a molecule neuro-oncologists Slide gene becoming the and alike using -- very program these much-needed failed. clear is the transition and have I before the the ability recurrent and slide, will building next case the adenoviral activator only
the benefit since with the X, show got in And data where lines update program. patients and our the we in -- words, this And you program So recurrent X really IL-XX. immunotherapy context, of called I things stand let's evidence of to last the with at look out Slide on we've glioblastoma glioblastoma want why significantly, new controlled call. production to other put from our information and that
major overall then, May effects is to -- with we've XX.X-month -- treating -- tumor. and recurrent kind at seeing ASCO this as and survival first average announced brain. in we median there we're Since follow-up The And related get for, an system X X.X patients of we're antitumor Phase as the the seeing trial, the data the I evidence bullet associated really brain In in with glioblastoma. expected was increasing indeed, activated across we months. of want point was the that hoped a we that immune I to that our
have really point X lines we So evidence that. to of that
-- with of -- immune a ratio T better had surviving systemic also management, than reversible IL-XX-mediated the their elevated associated line veledimex. immune one that Phase the can from that which first I And who control. the events there's simple again, increases the consistent in major postoperative by who doubt indeed, appear -- XXX% we've of of measure is the given There's T no to or drug-related reported then patients by of our cells received appears interferes were steroids, -- And driven immune recurrent predictable, survival survival in earlier, and is XXX% the the latter patients tune be seen these these patients The as the received now also is a Furthermore, of received adverse longer response. that that the as switch low-dose to this IL-XX. And cells words, activation steroids, who therapy. as with one context again, highlight really kind steroids data the rate strengths survival survival blood. presumably GBM entirely ratio, with ratio. peripheral ratio the for X of that that other And -- and stopping really, those directly And IL-XX activation. modulate suppressor the in can the levels we to trial to correlated killer to which, is effector the rapidly be IL-XX dose of for in lowest
data. remarkable next So at slide, think, really, look on X, let's some the Slide I
other So colleagues -- cells And the lesion, many we after is is And to red we a them, a And see they're not to crosshair tumors of IL-XX powerful lesion CDX words, patients. the into and cytokine these making And goes you also a interferon. with our T your that just Il-XX physician another And glioblastoma. smaller data this screen are in X T killer fight opportunity is biopsy we've infiltration had are patients against completion and cells the crosshair be being on are see of showing can to after importantly, in because brain called the sitting when this on glioma slide, getting instance, a remarkable gamma there's the for other the engaged there. that words active called In brain. these T see, weeks that in veledimex. in major that fight. we bullet these or has lesions They in can highlighting There's our that therapy. a new remarkably, that cells. these somebody's there's engaged neurosurgeon have
working. I So further we us no question why we're see increasingly switch now these effect there's think that we indeed understand is no IL-XX. Not that only provide And but these that data the the surviving. are question a seeing recipients confidence is what there's beneficial survival IL-XX and do is data, working, of
in announced we to on significantly, data you at last just I the at going to Francisco, trial data. recurrent he's he's And treating weeks you Chief to if think, I see has updated in more when also data, would, to you you Dr. -- we're on be survival. by, terms teaser, further prior presentation additional will with the IL-XX reinforce in evaluate engaged of that and on really delighted time Chiocca's will Chiocca on again, veledimex the Neuro-Oncology with the reinforce actor system. of May about how you survival study. the of presenting be Phase survival sweep Society Neurosurgery So our how gave months that we're XX, frame -- the we'll the patients you XX.X overall is the the a And action median way this, X -- and in in of I would, working. kind update IL-XX are obviously, in the think our you of to And you be to we surviving. slide I San Dr. a his mechanism able going if include in survival data. about adenoviral of And gone latest now to Harvard progress that And patients presentation is of I it'll update that's his of glioblastoma. immune bit on the from at once a where Slide the thrilled the terms program update is that these activator ligand Phase SNO
will call really Chicago on of these in control Dr. Additionally the provide in dosed so. doing not study some for veledimex update SNO Dr. an month, at announced And plus the delivery San our is we has on Stew last design of cancers. to present be Goldman Francisco, presentations trial. of for going Phase these to the patient company trial conference SNO, new forward pediatric the I a this to the Goldman first you of brain after Because adenovirus we're and will at treatment IL-XX data, discuss looking as to
you'll terrific the slide, from we've this IL-XX of the gliomas. we're the really I -- advancing trials, indeed progress data coming controlled that at Slide Phase positive -- from think really this next to -- and I our adenovirus so made alluding production that's see keeps I'm SNO. And what and XX in So on for
with on encouraging us year. where point discussed. as And trial feedback randomized registration treatment. our anti-PD-X really get we we is pivotal survival be and reminder, regular plans about will and data open that with study in I eligible randomized and looking I this of data, the going mentioned, our with trial. have to out success. recurrent to that if our as trial, based And glioblastoma quite Board And checkpoint best and is with the combination enrolling, Data XXX% of the that intervals here. tunable initiating from looks I commercial immune trial termination. We're enrolling. and trial, start as agencies slide reviewing who makes And combine Again, good forward the associated for Phase open IL-XX trial will agent yields it that be that data The the this on as design the our study, really really expect to -- this trial patients and preclinical mice. best us may same now Monitoring gives a the Safety this controlled excited for data inhibitor delighted really stereotactic to for be including Our We're to well on actions; frankly, that's I will also a addresses combination say later good, And the opening we of broadens company's early think needs this pediatric as the excited just especially the the trial initiate in comes population think the to the to to U.S. which we controlled as year. trial think patients randomized the opportunity regulatory various that at controlled the it look company. really trial, recommend and And
I've just and forward for As with before, a currently mentioned about unfold, we're strategic these be opportunities optimistic here, in drug. one IL-XX as more and partner with discussions. program I'll than and moving these this the as And study discussions we'll highlight we're advancing
Okay.
many, to T more therapies. scalable cells we've faster therapy make than we XX. T-cell available program. it's T the is that we're to of believe So again And gears And to now our effective the developed so this many technology and And we viral-based platform switch this non-viral more going this to modify cell patients. therapies engineering Slide therapy will genetic make is and T-cell And therapy gene cells. future can
culling and lay therapies think in the XX, very other issues costly, very in what weeks, cell recent therapies. Slide in really been thoughtful between solutions me headlines And is these struck some of that are is measured scale this the we've time have that cells. for on here press. the of we cost - strikes a current And and -- cell and the of is address is really what that XX quite XX So rapid think days. of comes are a recently-approved I - somewhere words, can T In I and and manufacturing T manufacturing
we're here, very how are manufacturing achieve to going be new unique Slide And under point-of-care, again, POC. get And on or industry. X core which will we're done, technologies look on rapid a this let's X XX to is is days. And that. do focused the us. to So in standard to ZIOPHARM for focused This, this
is genetically than cells. -- modified to transfer rather Sleeping the first The this Beauty virus system DNA of T
The to is survival provides after control And facilities. manufacturing signal the second critical inside to the cells this T of this cells, infusion. use that -- to of engineering modified cells be T T is the third in cytokine the switch the a a a than patient of rather switch the use are the and genetically grown that allows IL-XX, part
we've a production XX, standard tackling, how for this essentially, broken design. into is slide by the of down new T provide on So cells. this parts. ZIOPHARM its to is idea component This the was And
first-generation days. thrilled the T in the to -- this in team enter can modified is entering we currently done clinic anticipate be point-of-care that completed, trials. And cells next is we've Indeed, enrolling X of this less cusp in biology So be than this will genetically with the year. the on clinic manufactured second-generation really, trial the we're And trial. X and the
leukemia. the of survival were we'll As favorable and trial many X-week and this important mentioned lymphoma on And remarks, ago, a CAR have in with trials opening outcome using reminder, of manufacturing, his patients patients. as enrolled updates David showed first-generation with that patients initial and some years those our the
importantly, the Our T the both to to T patient you - trial after second-generation trial been need the really of before weeks confidence amount essentially also, - occur, takes would And third-generation and release can pressure-tested trial cells. followed shortening essentially those the gives time the two the and programmed; release trial. X release by the of shorten if this we you time manufacturing manufacture great to they've things within cells. punch, have it that and to Because our for get one-two second-generation us opening first-generation this the shortened the really cells
survival XX. to trial. enrolled second-generation have that who the I've Slide highlighted comes we're further very at with data updates of our going on we manufacturing. of cells. going and confidence used patients CAR-T We're the have addition because trial. information Beauty to to on these -- on ahead And patients. have updates infused first-generation on manufacturing Both our X That's going comment of in to the also the So going the regarding ASH looking comment We're to Anderson. system. persistence MD part to Sleeping And in Intrexon our our on presentations we're this rapid the about the partners point-of-care We're giving of preclinical
not I most on as patients. us really multi-year trial, follow-up mature, but months just of to, first-generation some -- our -- Our alluded years-long is providing now the
infuses a Our the lymphodepleting manufacturing this and of last alluded third-generation is really these the of And cells clinic tests the that to around second-generation T trial really of generating the exciting that progress I've to think enter point-of-care lot the our suite T release chemotherapy, enthusiasm year. the trials year are I the over and trial improvements CAR, to what's next cells. it really after in we as
will which T on our on well our update, MD is comment an our update at of part currently enrolling as also, as as We program, cells also Anderson. regulatory CDXX
is the CRADA this signed to he work therapies, us chose the Beauty Slide clinical progress. highlight T XX, and with just and really, the cells a modify which now this January in progressed -- CRADA we T where the year developing through He's doing tumor-specific So genetically to Sleeping pace respect the summary, rapid to XXXX let's Steve Rosenberg. we would stand system under writing of pace the the NCI. -- chose the we neoantigen-specific is T-cell partnership go with -- our like We've with January he Essentially, in with we're of to And progressed going we're of of and I be on through actually are the the process cells preclinical have really receptors. point, data. the -- to And the all cell to after neoantigens, where a genetically which to going to it's make because year. and we pressure-testing launch Rosenberg. trial T go tumors. are trial amazing to the to first develop scale-up And really within then why Dr. cancer, go company will trial, to the hallmark a validation This program next non-viral under we're of that personalized of this been at solid of clinical currently of be the be therapy Achilles this a has approach biology. T-cell go clinical year. after these direction able And done patients using And heel
quickly trial. fund be approximately funds the at Slide MD conducted of over Center under randomized At agreement. and the starting includes our can the update. really our reserves now XXXX, Center. MD operations prepayment quarter in support will into to quarter corporate approximately controlled sufficient at We to the cash million cash that fourth anticipate to the our we our of programs Cancer current -- go XX, And be cash research the Anderson these that million $XX.X plus Slide program resources from So rest have close $XX.X X on slides on unrestricted XX. Anderson Cancer we
for the remarks, we my are and let turn over prepared you Operator, may, those there? up then if and I me it questions. operator, to can open it So are
